Unia Europejska - chorwacki - EMA (European Medicines Agency)

sanofi b.v. - alglukozidaza alfa - vrsta ii za skladištenje glikogena - drugi gastrointestinalni trakt i metabolizam, lijekovi, - myozyme je indiciran za dugoročnu zamjensku enzimsku terapiju (ert) u bolesnika s potvrđenom dijagnozom bolesti pompe (nedostatak kiselina-a-glukozidaza). u bolesnika s kasnim početkom bolesti Помпе dokaz učinkovitosti ograničena.

Bośnia i Hercegowina - chorwacki - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - alglukozidaza alfa - prašak za koncentrat za rastvor za infuziju - 50 mg/1 boca - 1 bočica sa praškom za koncentrat za rastvor za infuziju sadrži: 50 mg alglukozidaza alfa

Czarnogóra - chorwacki - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

dio stranog druŠtva"sanofi - aventis" -podgorica - alglukozidaza alfa - prašak za koncentrat za rastvor za infuziju - 50mg

Unia Europejska - hiszpański - EMA (European Medicines Agency)

sanofi b.v. - alglucosidasa alfa - enfermedad de almacenamiento de glucógeno tipo ii - otros tracto alimentario y metabolismo de los productos, - myozyme está indicado para la terapia de reemplazo enzimático a largo plazo (tre) en pacientes con diagnóstico confirmado de enfermedad de pompe (deficiencia de ácido α-glucosidasa). en los pacientes con inicio tardío de la enfermedad de pompe la evidencia de eficacia es limitada.

Izrael - angielski - Ministry of Health

sanofi israel ltd - alglucosidase alfa - powder for concentrate for infusion - alglucosidase alfa 50 mg/vial - alglucosidase alfa - alglucosidase alfa - myozyme is indicated for long-term enzyme replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). the benefits of myozyme in patients with late-onset pompe disease have not been established.

Unia Europejska - angielski - EMA (European Medicines Agency)

sanofi b.v. - alglucosidase alfa - glycogen storage disease type ii - other alimentary tract and metabolism products, - myozyme is indicated for long-term enzyme-replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid-α-glucosidase deficiency).in patients with late-onset pompe disease the evidence of efficacy is limited.

Kanada - angielski - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - alglucosidase alfa - powder for solution - 50mg - alglucosidase alfa 50mg - enzymes

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

genzyme therapeutics ltd - alglucosidase alfa - powder for solution for infusion - 50mg

Izrael - hebrajski - Ministry of Health

sanofi israel ltd - alglucosidase alfa - אבקה להכנת תרכיז לאינפוזיה - alglucosidase alfa 50 mg/vial - alglucosidase alfa - alglucosidase alfa - myozyme is indicated for long-term enzyme replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). the benefits of myozyme in patients with late-onset pompe disease have not been established.

Unia Europejska - łotewski - EMA (European Medicines Agency)

sanofi b.v. - alglucosidase alfa - glikogēna uzglabāšanas slimības ii tipa - citas gremošanas trakta un metabolisma produkti, - myozyme ir indicēts ilgstošai enzīmu aizstājterapijai (ert) pacientiem ar apstiprinātu pompe slimības (skābes-α-glikozidāzes deficīta) diagnozi. pacientiem ar vēlīniem pompe slimība iedarbīgumu ir ierobežots.